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Impairment of neuronal autophagy is
implicated in the pathogenesis of
neurodegenerative proteinopathies.
However, little is known about the
extracellular cues that regulate neuronal
autophagy. Kim et al. show that activation
of Toll-like receptor 2 negatively regulates
neuronal autophagy, and
synucleinopathy lesions are rescued by
antagonizing TLR2.
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Impaired autophagy has been implicated in many
neurodegenerative diseases, such as Parkinson’s
disease (PD), and might be responsible for deposi-
tion of aggregated proteins in neurons. However,
little is known about how neuronal autophagy and
clearance of aggregated proteins are regulated.
Here, we show a role for Toll-like receptor 2
(TLR2), a pathogen-recognizing receptor in innate
immunity, in regulation of neuronal autophagy and
clearance of a-synuclein, a protein aggregated in
synucleinopathies, including in PD. Activation of
TLR2 resulted in the accumulation of a-synuclein
aggregates in neurons as a result of inhibition of
autophagic activity through regulation of the AKT/
mTOR pathway. In contrast, inactivation of TLR2
resulted in autophagy activation and increased
clearance of neuronal a-synuclein, and hence re-
duced neurodegeneration, in transgenic mice and
in in vitro models. These results uncover roles of
TLR2 in regulating neuronal autophagy and suggest
that the TLR2 pathway may be targeted for auto-
phagy activation strategies in treating neurodegen-
erative disorders.INTRODUCTION
Protein homeostasis (proteostasis) is vital for neuronal function
and survival, as most neurons are not renewable. Impaired pro-
teostasis results in protein aggregation and has been suggested
to be the crucial step in the pathogenesis of many neurodegen-
erative diseases. Maintaining the healthy neuronal proteostasis
state is, therefore, one of foremost importance. However, the
mechanism of how proteostasis is regulated in neurons remains
largely unknown.
Abnormal deposition of a-synuclein in neuron and glia is
implicated in a group of neurodegenerative diseases that
include Parkinson’s disease (PD), dementia with Lewy bodies
(DLB), and multiple system atrophy (MSA) (McCann et al.,C2014). In PD, the a-synuclein pathology initiates at specific
brain regions and disseminates to various anatomical regions
as the clinical symptoms progress (Braak and Del Tredici,
2008). Cell-to-cell transmission of a-synuclein aggregates
have been suggested to be involved in the pathological pro-
gression of the disease (Lee et al., 2014). The mechanisms of
a-synuclein aggregation and transmission are not entirely clear;
however, studies suggest that alterations in synthesis and
clearance processes play crucial roles (Bae et al., 2014; Kim
and Lee, 2008; Lee et al., 2014).
Macroautophagy (hereafter referred to as autophagy) is
a lysosome-dependent cellular degradation system that is
known to be responsible for the clearance of protein aggre-
gates in neuron (Menzies et al., 2015). Therefore, inhibition
of lysosomal and autophagic functions resulted in the accumu-
lation of a-synuclein aggregates in cells (Lee et al., 2004;
Webb et al., 2003). In contrast, activation of autophagy pro-
moted clearance of the cytoplasmic protein aggregates, such
as a-synuclein and polyglutamine proteins (Menzies et al.,
2015). These results led to the proposal that enhancement of
autophagic activity might be a promising therapeutic strategy
for neurodegenerative diseases (Ravikumar et al., 2004; Sarkar
et al., 2005, 2007).
Despite the importance of autophagy in proteostasis, the
regulation of neuronal autophagy is poorly understood. In
particular, very little is known about the extracellular cues
that regulate autophagy in the nervous system. However, regu-
lation of autophagy by extracellular stimuli has been studied
intensively in immune cells, because autophagy plays impor-
tant roles in response to extracellular pathogens (Delgado
and Deretic, 2009). Pattern recognition receptors (PRRs),
including Toll-like receptors (TLRs), are well-known regulators
of pathogen-related autophagy (Delgado and Deretic, 2009;
Delgado et al., 2008).
TLR2 has been suggested to play an important role in
the pathogenesis of neurodegenerative diseases through in-
volvement in neuroinflammatory processes. TLR2 is upregu-
lated in PD and DLB patients as well as in animal models
of neurodegenerative diseases, including Alzheimer’s disease
(AD) and PD/DLB (Kim et al., 2013; Letiembre et al., 2009). In
this study, we investigated the role of TLR2 signaling in the
regulation of autophagy and a-synuclein clearance in neu-
rons. We provide evidence that TLR2 signaling is inhibitoryell Reports 13, 771–782, October 27, 2015 ª2015 The Authors 771
Figure 1. Generation and Characterization
of A53T+Tlr2/ Mice
(A) Scheme of A53T+Tlr2/ double-tg mice gen-
eration. See Figure S1A for genotype analysis.
(B) Immunoblot analysis of Tx-soluble and Tx-
insoluble brain homogenates from non-tg and tg
mice (9 months old) for a-synuclein. See Figures
S1BandS1C fora-synuclein expression in themice.
(C) Representative immunofluorescence images of
non-tg and tg mice brains against human a-synu-
clein (top) and Tlr2 (bottom) (neocortex, 9 months
old). Sections were stained for a-synuclein (green),
TLR2 (red), and nuclei (DAPI, blue). Scale bar,
50 mm.
(D) Representative images of double immunolab-
eling analysis for Tlr2 with either microglial marker
(Iba-1) or neuronal cell marker (NeuN) in tg mice
brains. Both microglial cells (top) and neuronal
cells (bottom) showed immune-reactivity against
Tlr2 antibody in A53T+ mice brain, but not in
A53T+Tlr2/ mice brains (neocortex, 9 months
old). Scale bar, 25 mm.
(E and F) Co-localization image analysis of Tlr2/
Iba-1 (E) and Tlr2/NeuN (F) in non-tg and tg mice
brains (n = 6 per group; unpaired t test, *p < 0.05;
n.d., not detected). Data are represented as
mean ± SEM.for autophagy and, hence, for the clearance of a-synuclein
aggregates in neurons.
RESULTS
Tlr2 Deficiency Results in Reduced Neuronal
a-Synuclein Accumulation and Neurodegeneration in a
Mouse Model of Synucleinopathy
Our previous study demonstrated that oligomeric forms of
neuron-released a-synuclein induced the activation of micro-
glia by interaction with TLR2 on the surface of microglia (Kim
et al., 2013). To gain a comprehensive understanding of the
pathological roles of TLR2 in PD, we generated A53T+Tlr2/
mice by crossing transgenic mice (tg) expressing human
A53T a-synuclein (A53T+) and Tlr2 knockout mice (Tlr2/)
(Figures 1A and S1A). The mRNA levels of human a-synuclein
were not significantly affected by Tlr2 gene deletion, as deter-
mined by qPCR (Figure S1B; Table S1). However, the levels
of a-synuclein in Triton X-100-insoluble brain homogenates
were decreased significantly in A53T+Tlr2/ mice compared772 Cell Reports 13, 771–782, October 27, 2015 ª2015 The Authorswith those in A53T+ mice (Figures 1B
and S1C). Immunoreactivity against
a-synuclein also was reduced signifi-
cantly in neurons of A53T+Tlr2/ mice
compared to A53T+ mice (Figure 1C).
To verify Tlr2-expressing cells in the
brain, we performed immunofluorescence
analysis (Figures 1D–1F). Tlr2 was ex-
pressed in both NeuN-positive neurons
and Iba-1-positive microglia in the brain
(Figures 1D–1F). In contrast, Tlr2 was not
detected in either microglia or neurons inA53T+Tlr2/ (Figures 1D–1F) or Tlr2/ mice (data not shown).
Furthermore, the percentage of Tlr2-positive neurons was
increased in A53T+mice compared to the non-tgmice (Figure 1F).
To confirm the alterations of a-synuclein levels in tg mice, we
performed immunohistochemical analysis (Figures 2A–2E and
S2). The a-synuclein was highly expressed in neuronal cell
bodies and the neuropil throughout the brain in A53T+ mice (Fig-
ures 2A–2E and S2A). In contrast, levels of a-synuclein were
decreased significantly in both cell bodies (Figures 2A–2C and
2E) and the neuropil (Figures 2A and 2D) of A53T+Tlr2/ mice
compared to A53T+ mice. To further support our findings, we
used an antibody that specifically recognizes the C terminus of
human a-synuclein (Figures S2D–S2H). As expected, human
a-synuclein was not detected in non-tg or Tlr2/mice, but high-
ly expressed in neuronal cell bodies and the neuropil of A53T+
mice (Figures S2D–S2H). In contrast, human a-synuclein immu-
noreactivity clearly was decreased in A53T+Tlr2/ mice
compared to A53T+ mice (Figures S2D–S2H). Together, these
results suggest that neuronal TLR2 plays a role in the regulation
of steady-state levels of a-synuclein.
Figure 2. a-Synuclein Deposition, Neuroinflammation, and Neurodegeneration in Models of PD
(A) Representative immunohistochemical staining of a-synuclein in the neocortex, hippocampus, basal ganglia, and substantia nigra of 5-month age-matched
non-tg and tg mice brains. See Figure S2A for a-synuclein immunohistochemical analysis of 9-month age-matched group. Also see Figures S2D–S2H for human
a-synuclein immunohistochemical analysis. Scale bars, 250 mm (low magnification) and 25 mm (high magnification).
(B–E) Optical density analysis of immunohistochemical immunoreactivity of a-synuclein in neocortex (B), hippocampus (C), basal ganglia (D), and substantia nigra
(E) (n = 6 per group; one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001). Data are represented as mean ± SEM.
(F) Representative immunohistochemical staining of GFAP, Iba-1, and NeuN in neocortex/hippocampus (lowmagnification) and neocortex (highmagnification) of
5-month age-matched non-tg and tg mice brains. See Figures S2B and S2C for proinflammaotry cytokine gene expression. Scale bars, 250 mm (low magnifi-
cation) and 25 mm (high magnification).
(G–I) Optical density analysis of immunohistochemical immunoreactivity of GFAP (G), Iba-1 (H), and NeuN (I) in the neocortex regions (n = 6 per group; one-way
ANOVA, *p < 0.05, **p < 0.01). Data are represented as mean ± SEM.Overexpression of human a-synuclein has been shown to in-
duce neuroinflammation and neurodegeneration in mice (Hirsch
and Hunot, 2009; Long-Smith et al., 2009; Maries et al., 2003).
Likewise, in the neocortex of the A53T+ mice, immunohisto-
chemical analysis showed increases in astrogliosis (GFAP),
microgliosis (Iba-1), and neurodegeneration (NeuN) (Figures
2F–2I). In addition, the mRNA levels of pro-inflammatory cyto-
kine genes, such as TNF-a and IL-6, were increased in the
neocortices of A53T+ mice (Figures S2B and S2C). In contrast,
gene deletion of Tlr2 significantly reduced glial activation,
neuronal loss, and cytokine gene expressions in A53T+Tlr2/
mice (Figures 2F–2I, S2B, and S2C), suggesting that the re-
duction of a-synuclein levels in Tlr2-deficient mice alleviates
the pathogenic phenotypes, such as neuroinflammation and
neurodegeneration.CActivation of TLR2 Leads to Accumulation of
a-Synuclein Aggregates and a-Synuclein-Dependent
Neurotoxicity in Neurons
To investigate the mechanism of TLR2-mediated a-synuclein
accumulation, differentiated SH-SY5Y human neuroblastoma
cells (dSY5Y) were infected with either lentiviral vectors overex-
pressing a-synuclein (LV-a-Syn) or control vector (LV-control)
and treated with TLR2-specific agonist, pam3CSK4 (TLR1/2
agonist) (Figures 3A–3C). Expression of TLR2 in dSY5Y cells
was demonstrated by qPCR and the TLR2 ligand response
assay (Figures S3A and S3B). Immunoflourescence analysis
showed that the levels of a-synuclein were increased in TLR2
agonist-exposed cells (Figure 3A). In addition, the Triton-
insoluble a-synuclein oligomers were increased by TLR2 activa-
tion in cells (Figure 3B). In contrast, pre-treatment with TLR2ell Reports 13, 771–782, October 27, 2015 ª2015 The Authors 773
functional blocking antibody (T2.5) significantly inhibited the
agonist-induced accumulation of a-synuclein oligomers in cells
(Figure 3C).
To confirm the involvement of TLR2 in the accumulation of
a-synuclein oligomers in neuronal cells, we constructed a
TLR2 knockdown lentiviral vector (LV-sh.TLR2) (Figures
S4A and S4B). Knockdown of TLR2 expression decreased
IkB degradation by TLR2 agonist (Figure S4C), and it sig-
nificantly reduced the TLR2 agonist-induced accumulation
of a-synuclein oligomers in dSY5Y cells (Figure 3D). Over-
expression of a-synuclein showed cytotoxicity in dSY5Y
cells, and activation of TLR2 exacerbated the cytotoxicity
(Figures 3E and S3C). In contrast, knockdown or functional
blocking of TLR2 alleviated the cytotoxicity induced not
only by a-synuclein overexpression alone but also by a-syn-
uclein expression with TLR2 activation (Figures 3E and S3C).
These results suggest that activation of TLR2 causes accu-
mulation of cytotoxic a-synuclein oligomers in neuronal
cells.
Knockdown of TLR2 Ameliorates a-Synuclein Pathology
and Motor Behavioral Deficits in a Mouse Model of PD
To further confirm the role of TLR2 in a-synuclein pathology,
we delivered the LV-sh.TLR2 into the hippocampus and
the striatum of another human a-synuclein tg mouse line
(a-Syn tg, D Line), which replicates some of the behavioral
and neuropathological features similar to those observed in
PD (Rockenstein et al., 2002; Figure 4). Delivery of LV-
sh.TLR2 reduced the expression of Tlr2 in the hippocampus
of both non-tg and a-Syn tg mice (Figures 4A, 4B, and S4D)
and resulted in a significant decrease of a-synuclein levels
(Figures 4A, 4C, and S4D). The expressions of the striatal
Tlr2 and the a-synuclein accumulation also were decreased
by injection of LV-sh.TLR2 (data not shown). The a-Syn tg
mice showed astrogliosis and microglia activation (Kim
et al., 2013; Spencer et al., 2014), and delivery of LV-
sh.TLR2 significantly decreased both microglia activation
and astrogliosis in this model (Figures 4A, 4D, and 4E).
Similar to our previous results, immunohistochemical anal-
ysis showed that expression of Tlr2 was increased in the
a-Syn tg mice compared to non-tg mice (Kim et al., 2013;
Figures 4A, 4B, and S4D).
To investigate the effects of the TLR2 knockdown on motor
behavior in a-Syn tg mice, we performed the beam break test
using non-tg and a-Syn tg mice, which were injected with either
LV-sh.control or LV-sh.TLR2 (Figures 4F and 4G). The a-Syn tg
mice showed an increment of the beam break numbers (Valera
et al., 2015); however, it was significantly decreased by the in-
jection of LV-sh.TLR2 (Figure 4F). The numbers of beam breaks
obtained from non-tg and a-Syn tg mice were decreased by
daily repetition tests, but the daily reduction rate of a-Syn tg
mice was significantly slower than the rates obtained from
non-tg mice (Figure 4G). Interestingly, LV-sh.TLR2-injected
a-Syn tg mice showed a similar reduction rate of daily beam
break numbers as non-tg mice (Figure 4G). Taken together,
these results suggest that knockdown of TLR2 ameliorates mo-
tor behavioral deficits and a-synuclein pathology in a mouse
model of PD.774 Cell Reports 13, 771–782, October 27, 2015 ª2015 The AuthorsActivation of Neuronal TLR2 Leads to a-Synuclein
Accumulation via Autophagy Dysregulation through
AKT/mTOR Activation
Since mRNA levels of a-synuclein were not affected by Tlr2
gene deletion (Figure S1B), we hypothesized that protein
degradation systems are regulated by TLR2 activation. In
particular, we examined the autophagy system, an active degra-
dation mechanism for aggregation-prone proteins (Kiselyov
et al., 2007). The a-synuclein-overexpressing dSY5Y cells were
treated with pam3CSK4 together with either the autophagy
inhibitor (bafilomycin A1) or autophagy inducer (rapamycin) (Fig-
ure 5A). Activation of TLR2 significantly increased the accumula-
tion of a-synuclein oligomers and p62/SQSTM1 in dSY5Y cells
(Figure 5A). Inhibition of autophagy also resulted in the accumu-
lation of a-synuclein oligomers and p62/SQSTM1 (Figure 5A).
Co-treatment of cells with pam3CSK4 and the autophagy inhib-
itor did not further increase the accumulation of a-synuclein from
the bafilomycin A1 treatment alone (Figure 5A), suggesting that
the effects of the TLR2 agonist on a-synuclein are exerted
through the autophagy pathway. However, the co-treatment
showed an additive increment of p62/SQSTM1 accumulation
(Figure 5A). The reason for additive increment of p62/SQSTM1
expression probably stems from the positive-transcriptional
feedback by autophagy (Sahani et al., 2014). Consistent with
these results, induction of autophagy alleviated the effect of
TLR2 agonist on the accumulation of a-synuclein oligomers
and p62/SQSTM1 in dSY5Y cells (Figure 5A).
To visualize live autophagy flux, dSY5Y cells were infectedwith
either LV-LC3-GFP or LV-LC3-GFP-mCherry (pH-sensitive-GFP-
mCherry tag) (Figures 5C, 5D, and S5A). Treatment of rapamycin
increased the number of LC3-GFP puncta (Figures 5C and S5A)
and LC3-mCherry puncta (Figure 5D) in dSY5Y cells; however,
activation of TLR2 decreased the number of LC3-GFP and
LC3-mCherry puncta, while increasing a-synuclein immunoreac-
tivity (Figures 5C, 5D, and S5A). In addition, co-treatment of rapa-
mycin with pam3CSK4 significantly decreased the accumulation
of a-synuclein caused by pam3CSK4 in the cells and increased
formation of LC3-GFP and LC3-mCherry puncta, suggesting
that rapamycin, a mammalian target of rapamycin (mTOR) inhib-
itor, could suppress TLR2-mediated autophagy inhibition (Fig-
ures 5C and 5D). Taken together, these results suggest that
activation of TLR2 results in the accumulation of a-synuclein via
autophagy inhibition, which can be reversed by rapamycin-medi-
ated autophagy induction.
To verify the regulation of autophagy by TLR2, we constructed
and infected dSY5Y cells with either LV-ATG7 or LV-sh.ATG7
(Figure 5B). Interestingly, overexpression of ATG7 signifi-
cantly decreased the accumulation of a-synuclein oligomers by
pam3CSK4 as well as the basal levels of a-synuclein oligomers
in the cells (Figure 5B). In contrast, knockdown of ATG7 increased
the basal levels of a-synuclein oligomers, but did not further in-
crease the accumulation of a-synuclein oligomers from the indi-
vidual treatments, suggesting that the effects of the TLR2 agonist
are exerted through the autophagy pathway (Figure 5B).
We next infected neuronal cells with the LV-sh.TLR2 to con-
firm the regulation of autophagy by TLR2 (Figure 5E). As shown
before (Figure 3D), TLR2 agonist-driven accumulation of a-syn-
uclein oligomer and p62/SQSTM1 were completely inhibited by
Figure 3. Accumulation of Cytotoxic a-Syn-
uclein Oligomers by TLR2 Activation in
Neuronal Cells
(A–C) The dSY5Y cells were infected with either
LV-control or LV-a-Syn and treated with
pam3CSK4 (10 mg/ml) for 24 hr. See Figures S3A
and S3B for TLR2 expression and activation in
dSY5Y cells.
(A) The a-synuclein-expressing dSY5Y cells were
immunolabeled with antibody against human
a-synuclein (syn211). Fluorescence intensity was
analyzed in ten randomly chosen areas (n = 3;
unpaired t test, ***p < 0.001). Data are represented
as mean ± SEM. Scale bar, 20 mm.
(B) Western blot analysis for Tx-insoluble and Tx-
soluble fractions. Tx-insoluble a-synuclein olig-
omer levels were determined by densitometric
quantification (n = 3; unpaired t test, *p < 0.05).
Data are represented as mean ± SEM.
(C) Effect of TLR2 functional blocking antibody
(T2.5) in the accumulation of a-synuclein oligo-
mers by TLR2 agonist. The a-synuclein-ex-
pressing dSY5Y cells were treated with IgG
(10 mg/ml) or T2.5 (10 mg/ml) for 30 min before
the addition of pam3CSK4 (10 mg/ml). Tx-insol-
uble a-synuclein oligomer levels were deter-
mined by densitometric quantification (n = 3;
one-way ANOVA, **p < 0.01, ***p < 0.001;
n.s., not significant). Data are represented as
mean ± SEM.
(D) Effect of TLR2 knockdown in the accumula-
tion of a-synuclein oligomers by TLR2 agonist.
The dSY5Y cells were infected with either a com-
bination of LV-sh.control/LV-a-Syn or LV-a-Syn/
LV-sh.TLR2 and then treated with pam3CSK4
(10 mg/ml) for 24 hr (n = 4; unpaired t test,
*p < 0.05). Data are represented as mean ± SEM.
See Figures S4A–S4C for construction and vali-
dation of LV-sh.TLR2.
(E) Cell viability analysis in dSY5Y cells. The dSY5Y cells were infected with LV-control, LV-sh.control, LV-GFP, LV-a-Syn/LV-sh.control, or LV-a-Syn/LV-
sh.TLR2 and then treated with pam3CSK4 (10 mg/ml) for 24 hr (n = 4; one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant). Data are
represented as mean ± SEM. See Figure S3C for cell viability analysis with TLR2 functional blocking antibody (T2.5).knockdown of TLR2 in dSY5Y cells (Figure 5E). Moreover, the
accumulation of p62/SQSTM1 occurred 6 hr prior to the accu-
mulation of a-synuclein oligomers in pam3CSK4-exposed cells
(Figure S5B). Activation of TLR2 also increased accumulation
of polyubiquitinated proteins, well-known p62/SQSTM1 sub-
strates (Figure S5C). The pam3CSK4-driven accumulation of
polyubiquitinated proteins was reduced by knockdown of
TLR2, which also resulted in increased levels of LAMP2A, indi-
cating that the lysosomal contents might be increased as a
compensatory response against autophagy failure (Figure S5C).
Next we investigated the alteration of mTOR, because auto-
phagy inhibition by the TLR2 activation was recovered by
rapamycin (Figures 5F and 5G). Surprisingly, the phosphoryla-
tion of mTOR (S2481) was increased by the activation of
TLR2 in dSY5Y cells (Figure 5F). In addition, the activation of
TLR2 increased phosphorylation of AKT (S473), a well-known
mTOR activator (Janku et al., 2011; Figure 5F). In contrast,
knockdown of TLR2 inhibited the pam3CSK4-driven phosphor-
ylation of both AKT and mTOR, indicating that TLR2 mediates
the AKT/mTOR-signaling pathway consistent with previousCstudies (Schmitz et al., 2008; Figure 5G). Furthermore, activa-
tion of TLR2 reduced the levels of lysosomal a-synuclein in
a-synclein-expressing cells (V1S cells) (Figure S5D), the result
that is consistent with the interpretation that activation of
TLR2 interferes with the autophagosome formation through
the AKT/mTOR activation.
We next verified our findings in human neural precursor cells
(hNPCs) (Figure 6). The hNPC expressed a slightly higher level
of TLR2 mRNA than dSY5Y cells (Figure 6A; Table S1). The
TLR2 mRNA level was decreased significantly by infection of
LV-sh.TLR2 in hNPCs (Figure 6B). Activation of TLR2 induced
the accumulation of a-synuclein oligomers and p62/SQSTM1 in
hNPCs (Figure 6C). Knockdown of TLR2 inhibited the agonist-
driven accumulation of both a-synuclein and p62/SQSTM1 (Fig-
ure 6D). More interestingly, activation of TLR2 increased phos-
phorylated AKT (S473), while the basal levels of phosphorylated
AKT were decreased significantly by TLR2 knockdown, which
may be related to reduced expression of a-synuclein in LV-
sh.TLR2-infected hNPCs (Figure 6D). Activation of TLR2 also
increased a-synuclein immunoreactivity and reduced LC3-GFPell Reports 13, 771–782, October 27, 2015 ª2015 The Authors 775
Figure 4. Knockdown of Tlr2 Ameliorates
a-Synuclein Pathology and Behavioral Defi-
cits in a-Syn tg Mice
Either LV-sh.control or LV-sh.TLR2 was injected
into the hippocampus and striatum of non-tg and
a-Syn tg (D line) mice.
(A) Representative immunohistochemical staining
of Tlr2, a-synuclein, GFAP, and Iba-1 in neocortex/
hippocampus (low magnification) and hippocam-
pus (high magnification) of non-tg and a-Syn tg
mice. See Figure S4D for a-synuclein/TLR2 double
immune-labeling analysis. Scale bars, 250 mm (low
magnification) and 25 mm (high magnification).
(B–E) Optical density analysis of immunohisto-
chemical immunoreactivity of Tlr2 (B), a-synuclein
(C), GFAP (D), and Iba-1 (E) in the hippocampus
(n = 6 per group; one-way ANOVA, *p < 0.05,
**p < 0.01, ***p < 0.001; n.s., not significant). Data
are represented as mean ± SEM.
(F and G) Motor behavioral analysis of non-tg
and a-Syn tg mice using beam break test. Total
beam breaks (F) and daily beam breaks (G)
were recorded (n = 5 per group; one-way ANOVA,
*p < 0.05, **p < 0.01). Data are represented as
mean ± SEM.puncta in hNPCs (Figure 6E). Cytotoxicity analysis showed that
overexpression of a-synuclein induced neuronal cytotoxicity,
which was further increased by the activation of TLR2 (Figures
6F and 6G). Knockdown of TLR2 protected neurons from a-syn-
uclein-induced cytotoxicity (Figures 6F and 6G). These results
suggest that activation of TLR2 results in the accumulation of
a-synuclein oligomers and neuronal toxicity through AKT/
mTOR-mediated autophagy inhibition in human neurons.
TLR2 Gene Depletion Promotes a-Synuclein Clearance
by Removing Autophagy Inhibition In Vivo
To validate our findings in vivo, we investigated alterations
of autophagy markers in mouse models (Figure S6). Double-
labeling analysis showed a reduction of a-synuclein levels in776 Cell Reports 13, 771–782, October 27, 2015 ª2015 The AuthorsA53T+Tlr2/ mice compared to A53T+
mice (Figure S6A). In contrast, immuno-
reactivity against LC3 was increased in
both Tlr2/ and A53T+Tlr2/ mice,
and the latter animals showed higher
levels of LC3 than the former (Fig-
ure S6A). A53T+ mice showed higher
levels of p62/SQSTM1 than the non-tg
mice (Figure S6C), and deletion of Tlr2
completely reversed the a-synuclein-
induced p62/SQSTM1 accumulation
(Figure S6C). Expression levels of
Beclin-1 and Lamp2a were not altered
in A53T+ and A53T+Tlr2/ mice (Figures
S6B and S6C). However, LC3I/LC3II
conversion and Atg12-Atg5 conjugation
were increased in A53T+Tlr2/ mice
(Figure S6B). The number of autophago-
somes was increased significantly inboth Tlr2/ and A53T+Tlr2/ mice (Figures S6D and S6F).
Furthermore, synaptic degeneration observed by electron mi-
croscopy in A53T+ mice was reduced significantly by Tlr2
gene depletion (Figures S6D and S6E). These findings are
consistent with the interpretation that TLR2 depletion,
and perhaps inactivation, restores the autophagy process,
thereby preventing the accumulation of a-synuclein and
neurodegeneration.
Inhibition of AKT Activity Results in Decreased
a-Synuclein Accumulation by Neuronal TLR2 Activation
To validate the roles of AKT signaling in the regulation of neuronal
autophagy by TLR2, dSY5Y cells were treated with GSK690693,
an AKT inhibitor. The a-synuclein-overexpressing dSY5Y cells
Figure 5. Impairment of Autophagy by TLR2 Activation through AKT/mTOR Signaling Process Results in Accumulation of a-Synuclein
Aggregates in Neuronal Cells
(A) The dSY5Y cells were infected with LV-a-Syn and pre-treated with bafilomycin A1 (Baf.A1, 100 nM) for 30 min, prior to adding pam3CSK4 (10 mg/ml) or
simultaneously being treated with pam3CSK4 and rapamycin (100 mM). After 24 hr incubation, whole-cell lysates were analyzed by western blot analysis. The
levels of a-synuclein oligomers and p62/SQSTM1 were determined by densitometric quantification (n = 3; one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001;
n.s., not significant). Data are represented as mean ± SEM.
(B) The dSY5Y cells were infected with the indicated combination of lentiviral vectors and treated with pam3CSK4 (10 mg/ml) for 24 hr. Whole-cell lysates were
analyzed by western blot analysis. The levels of a-synuclein oligomers and p62/SQSTM1 were determined by densitometric quantification (n = 3; one-way
ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant). Data are represented as mean ± SEM.
(C and D) The dSY5Y cells were infected with either LV-a-Syn/LV-LC3-GFP or LV-LC3-GFP-mCherry (pH-sensitive-GFP-mCherry tag) and then treated with
pam3CSK4 (10 mg/ml) and/or rapamycin (100 mM) for 24 hr. See also Figure S6 for autophagy analysis in non-tg and tg mice brains.
(C) Formations of LC3-GFP puncta (green) and immunoreactivity of a-synuclein (red) were analyzed by confocal microscope. LC3-GFP grains and a-synuclein
fluorescence intensity were analyzed in ten randomly chosen areas from three independent experiments (n = 3; one-way ANOVA, *p < 0.05, **p < 0.01, ***p <
0.001). Data are represented as mean ± SEM. Scale bar, 20 mm. See Figure S5A for LV-control/LV-LC3-GFP-delivered control experiment.
(D) Formations of LC3-mCherry puncta (red) were analyzed by confocal microscope. The numbers of LC3-mCherry grains were analyzed in ten randomly chosen
areas from three independent experiments (n = 3; one-way ANOVA, ***p < 0.001). Data are represented as mean ± SEM. Scale bar, 20 mm.
(E) The dSY5Y cells were infected with either a combination of LV-a-Syn/LV-sh.control or LV-a-Syn/LV-sh.TLR2 and pre-treated with bafilomycin A1 (100 nM) for
30min, prior to adding pam3CSK4 (10 mg/ml) or simultaneously being treated with pam3CSK4 and rapamycin (100 mM). After 24-hr incubation, whole-cell lysates
were analyzed by western blot analysis. The levels of a-synuclein oligomers and p62/SQSTM1 were determined by densitometric quantification (n = 3; one-way
ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001). Data are represented as mean ± SEM. See Figure S5B for time-course analysis of a-synuclein and p62/SQSTM1
accumulation by TLR2 activation. Also see Figures S5C and S5D for western blot analysis for ubiquitin, Lamp2a, and lysosomal a-synuclein.
(F) The dSY5Y cells were treated with pam3CSK4 (10 mg/ml) for the indicated hours and whole-cell lysates were analyzed by western blot analysis. The levels of
phosphorylated AKT (S473) and phosphorylated mTOR (S2481) were determined by densitometric quantification (n = 3; one-way ANOVA, *p < 0.05, **p < 0.01,
***p < 0.001). Data are represented as mean ± SEM.
(G) The dSY5Y cells were infected with LV-sh.control or LV-sh.TLR2 and treated with pam3CSK4 (10 mg/ml) for 1 hr. Whole-cell lysates were analyzed by western
blot analysis. The levels of phosphorylated AKT (S473) and phosphorylated mTOR (S2481) were determined by densitometric quantification (n = 3; one-way
ANOVA, *p < 0.05, **p < 0.01). Data are represented as mean ± SEM.
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Figure 6. Activation of TLR2 Inhibits Autophagy and Induces Accumulation of a-Synuclein in Human Neural Precursor Cells
(A) ThehumanTLR2mRNA levels fromdSY5Ycells andhumanneural precursorcells (NPCs) (n=4; unpaired t test, * **p <0.01). Dataare representedasmean±SEM.
(B) Knockdown of TLR2 in NPCs by LV-sh.TLR2 infection (n = 4; unpaired t test, ***p < 0.001). Data are represented as mean ± SEM.
(C) NPCs were infected with LV-control or LV-a-Syn and treated with pam3CSK4 (10 mg/ml) for 24 hr. Whole-cell lysates were analyzed by western blot analysis.
The levels of a-synuclein oligomers and p62/SQSTM1 were determined by densitometric quantification (n = 3; unpaired t test, *p < 0.05, **p < 0.01; n.d., not
detected). Data are represented as mean ± SEM.
(D) NPCswere infectedwith either a combination of LV-sh.control/LV-a-Syn or LV-sh.TLR2/LV-a-Syn and treatedwith pam3CSK4 (10 mg/ml) for 24 hr.Whole-cell
lysates were analyzed by western blot analysis. The levels of a-synuclein oligomers and phosphorylated AKT were determined by densitometric quantification
(n = 3; one-way ANOVA, *p < 0.05, ***p < 0.001). Data are represented as mean ± SEM.
(E) NPCs were infected with either a combination of LV-control/LV-LC3-GFP or LV-a-Syn/LV-LC3-GFP and treated with pam3CSK4 (10 mg/ml) for 24 hr. For-
mations of LC3-GFP puncta (green), a-synuclein immunoreactivity (red, Syn211), and nuclei (DAPI, blue) were analyzed by confocal microscope. LC3-GFP grains
and a-synuclein fluorescence intensity were analyzed in ten randomly chosen areas (n = 3; one-way ANOVA, *p < 0.05, ***p < 0.001). Data are represented as
mean ± SEM. Scale bar, 20 mm.
(F and G) Cytotoxicity analysis in NPCs. NPCs were infected with LV-sh.control, LV-a-Syn/LV-sh.control, or LV-a-Syn/LV-sh.TLR2 and treated with pam3CSK4
(10 mg/ml) for 24 hr. Cytotoxicity was determined by cell viability assay (F) and number of dead cells (G) (n = 4; one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).
Data are represented as mean ± SEM.
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Figure 7. Model for a-Synuclein Accumula-
tion by Autophagy Dysregulation via TLR2/
AKT/mTOR-Signaling Pathway in Neuron
(A) The dSY5Y cells were infected with LV-
a-Syn and treated with pam3CSK4 (10 mg/ml) or
simultaneously treated with pam3CSK4 and
GSK690693 (1 or 10 mM) for 24 hr. Whole-cell ly-
sates were analyzed by western blot analysis. The
levels of a-synuclein oligomers and p62/SQSTM1
were determined by densitometric quantification
(n = 3; one-way ANOVA, *p < 0.05, **p < 0.01, ***p <
0.001; n.s., not significant). Data are represented
as mean ± SEM.
(B) Activation of TLR2 induces activation of AKT/
mTOR signaling, thereby inhibiting autophagy in
neurons and resulting in the accumulation of
a-synuclein oligomers and neurotoxicity. This
model suggests that both regulation of a-synuclein
oligomerization and TLR2/downstream signaling
are potential therapeutic targets for synucleino-
pathies, including PD and DLB. See also Figure S7.were treated with pam3CSK4 together with two different con-
centrations of GSK690693 (Figure 7A). As shown before (Figures
3, 5, 6, and S5B), activation of TLR2 increased the accumula-
tion of a-synuclein oligomers in neuronal cells (Figure 7A).
Surprisingly, treatment with GSK690693 significantly decreased
the accumulation of a-synuclein and p62/SQSTM1 caused
by pam3CSK4 in the cells (Figure 7A), suggesting that
GSK690693, an AKT inhibitor, could suppress TLR2-mediated
autophagy inhibition. Taken together, these results suggestCell Reports 13, 771–782that activation of TLR2 results in the
accumulation of a-synuclein via AKT/
mTOR-mediated autophagy inhibition in
neurons.
DISCUSSION
In this paper, we show how neuronal
a-synuclein pathology is regulated by
extracellular signals. Activation of TLR2
resulted in a-synuclein accumulation
through an AKT/mTOR-dependent inhibi-
tion of autophagy. In contrast, genetic
and pharmacological inactivation of the
TLR2 and TLR2 downstream signaling re-
sulted in autophagy activation, causing a
dramatic decrease of a-synuclein aggre-
gation in neurons (Figure 7B). This work
provides a significant advancement in
our understanding of how neuronal auto-
phagy and clearance of neuronal protein
aggregates are regulated by extracellular
signals.
Although much attention has been paid
to the intracellular processes of a-synu-
clein synthesis and degradation, not
much is known about the extracellular
cues that regulate the intracellular levels
of the protein (Kim and Lee, 2008). Recent studies showed
the alteration of a-synuclein expression by extracellular cues,
including growth factors and small molecules (Clough and
Stefanis, 2007; Leng and Chuang, 2006; Mash et al., 2003).
Nerve growth factor and basic fibroblast growth factor increased
the expression of a-synuclein through the mitogen-activated
protein kinase pathway (Clough and Stefanis, 2007). Expression
of a-synuclein also is regulated by bioactive small mole-
cules, including valproic acid and cocaine (Leng and Chuang,, October 27, 2015 ª2015 The Authors 779
2006; Mash et al., 2003). However, here we showed how extra-
cellular cues alter the level of a-synuclein through regulation of
the intracellular process via gene expression. In particular, we
demonstrated that TLR2, a cell surface receptor, regulates the
level of a-synuclein through intracellular autophagy processes
in neurons.
The roles of TLRs and TLR downstream-signaling cascades
have been investigated extensively in microglia and astrocytes
through their role in neuroinflammation; however, little is known
of TLRs’ functions in neurons. Regardless, neuronal expres-
sions of TLRs have been demonstrated by multiple studies
(Liu et al., 2014). Expressions of TLR1, TLR2, TLR3, and
TLR4 have been detected in human NT2-N neuronal cell line
(Lafon et al., 2006). A TLR4 agonist, lipopolysaccharide (LPS),
induced expression of TNF-a, IL-6, CCL5, and CXCL1 in mouse
cortical neurons (Leow-Dyke et al., 2012). In addition, TLR7
activation increased expression of TNF-a and IL-6 in murine
primary neurons (Liu et al., 2013). Neurons also express the
TLR downstream-signaling proteins, such as Myd88 and Trif
(Chen et al., 2011). Furthermore, pathological and physiological
functions of neuronal TLR have been discussed (Okun et al.,
2011). A recent study showed that expression and activation
of neuronal TLR2 and 4 contributed to neurodegeneration by
ischemic stroke (Tang et al., 2007). Studies also have sug-
gested the roles of TLRs, such as TLR3, TLR7, and TLR8, in
neural morphogenesis (Liu et al., 2014). Activation of TLR3
induces growth-cone collapse and inhibits neurite outgrowth
in cultured dorsal root ganglion, cortical, and hippocampal neu-
rons (Cameron et al., 2007). Activation of TLR7 and TLR8 also
negatively regulates neurite outgrowth in mouse cortical neu-
rons (Liu et al., 2013; Ma et al., 2006). However, the mechanism
as to how TLRs regulate neurite outgrowth is not understood,
nor are the roles of TLRs in other neuronal functions. In this
study, we also found that neurons and SH-SY5Y human neuro-
blastoma cells express TLR2 and react in response to TLR2-
specific agonists.
The mechanism underlying the TLR-mediated autophagy re-
gulation is largely unknown. However, a recent study demon-
strated that activation of TLRs induced activation of mTOR
via the phosphoinositide 3 kinase/AKT pathway in bone
marrow-derived macrophages and myeloid dendritic cells
(DCs) (Schmitz et al., 2008). In addition, rapamycin and
Myd88/Trif double knockout inhibited pam3CSK4-driven phos-
phorylation of mTOR in the same cells (Schmitz et al., 2008).
Although this study did not link the mTOR activation to auto-
phagy regulation, plenty of other studies already demonstrated
the suppression of autophagy by mTOR activation (Janku et al.,
2011). In our study, we also found activation of AKT and
mTOR by TLR2 activation in neurons; knockdown of TLR2
expression intervened the activation of AKT and, therefore,
activated autophagy. These results suggest that neurons also
utilize the AKT/mTOR pathway in TLR2-induced regulation of
autophagy.
Although activation of TLRs induced mTOR activation and,
thus, autophagy inhibition, some studies showed an activation
of autophagy by TLR signaling in immune cells. We still do not
know what determines the dichotomy between the activation
and inhibition of autophagy by activation of the TLR-signaling780 Cell Reports 13, 771–782, October 27, 2015 ª2015 The Authorspathway in immune cells. However, herein, we clearly showed
direct autophagy regulation by neuronal TLR2 resulting in a-syn-
ucleinopathy. This evidence suggests the existence of a special-
ized TLR2/autophagy regulatory mechanism, which might be
determined by cell type specificity. Perhaps, one can speculate
that in the presence of pathogens, TLR2 activation in microglia
activates autophagy to clear the pathogens, while TLR2 activa-
tion in neurons inhibits autophagy to reduce metabolic rates in
an effort to survive in difficult times.
The results of our study have significant implications in therapy
for PD and related synucleinopathies. We showed that TLR2
deficiency and inhibition could activate autophagy and decrease
the levels of a-synuclein oligomers in neurons. These results
suggest therapeutic potential for antagonizing the TLR2 pathway
in reducing synucleinopathy lesions. Previously, we have shown
that, in microglia, TLR2 is activated by a-synuclein oligomers
secreted from neurons and induces proinflammatory responses
(Kim et al., 2013). This study demonstrated that blocking TLR2
signaling could alleviate a-synuclein-induced inflammation in
mice. In addition, these findings allow speculation that the
neuron-released a-synuclein oligomers may activate neuronal
TLR2, which results in autophagy disruption and a-synuclein
deposition. Therefore, antagonizing the TLR2 pathway might
have therapeutic benefits through both neuron-based and
microglia-based mechanisms. In neurons, the inhibition of
TLR2 induces autophagy and decreases the levels of oligomeric
a-synuclein, hence reducing the a-synuclein burden, while in mi-
croglia, TLR2 inhibition reduces proinflammatory responses trig-
gered by neuron-secreted a-synuclein oligomers (Figure S7).
Taken together, we suggest that TLR2 and the downstream
signaling may be therapeutic targets that can act on both neu-
rons and glia, alleviating both synucleinopathy lesions and
neuroinflammation.EXPERIMENTAL PROCEDURES
Animals, Generation of Double Transgenic Mice, and Delivery of
Lentiviral Vectors
C57Bl/6 and A53T [B6.Cg-tg(Thy1-SCNA*A53T)1Sud/J] mice were purchased
from the Jackson Laboratory (Lee et al., 2011). Tlr2-knockout mice were ob-
tained from Oriental Bioservice (Takeuchi et al., 1999). Transgenic mice ex-
pressing wild-type human a-synuclein under the PDGF-b promoter (a-Syn
tg, D line) were described elsewhere (Masliah et al., 2000). A53T+Tlr2/
mice were generated as depicted in Figure 1A. A53T+Tlr2/mice were gener-
ated in a two-step process as follows: (1) A53T+ mice were bred with Tlr2/
mice to generate A53T+Tlr2+/ mice, and (2) A53T+Tlr2+/ mice also were
crossed with A53T+Tlr2+/mice to generate A53T+Tlr2/mice. Mice positive
for human a-synuclein (A53T) and negative for Tlr2 were determined by PCR
genotyping and western blot analysis (Figure S1). Two different-age mice
groups (5 months and 9 months) were used for this study.
To determine the roles of Tlr2 in a model of PD, we delivered either LV-
sh.control or LV-sh.TLR2 into non-tg and a-Syn tg mice brains as previously
described (Spencer et al., 2014). Two microliters of either LV-sh.control or
LV-sh.TLR2 (1.9 3 108 infection units) was unilaterally stereotaxically injected
into hippocampus (anterior-posterior [AP], 2.0 mm; medial-lateral [ML],
1.5 mm; and dorsal-ventral [DV], 1.3 mm) and striatum (AP, 1.0 mm; ML,
1.5 mm; and DV,3.0 mm) of the right hemisphere. Then, 5 weeks post-injec-
tion, brains were processed for immunohistochemistry analysis. All proce-
dures for animal use were approved by Konkuk University’s Animal Care
and Use Committee (non-tg, Tlr2/, A53T+, and A53T+Tlr2/ mice) under
protocol KU11023-1 and the Institutional Animal Care and Use Committee at
University of California, San Diego (non-tg and a-Syn tg mice) under protocol
S02221.
Immunofluorescence, Immunohistological, and Neuropathological
Analyses
The procedure for immunofluorescence analysis of cells and brain sections
has been described elsewhere (Lee and Lee, 2002; Spencer et al., 2014; Valera
et al., 2015). Briefly, SH-SY5Y cells and NPCswere seeded onto poly-L-lysine-
coated coverslips or matrigel-coated coverslips, respectively. After differenti-
ation, infection, and treatment, cells were fixed with 4% paraformaldehyde.
Coverslips were incubated with primary antibodies and fluorescence-labeled
secondary antibodies in sequence. Blind-coded vibratome brain sections
were incubatedwith primary antibodies at 4C, followed by fluorescein isothio-
cyanate (FITC) or biotinylated secondary antibodies, avidin D-HRP (ABC elite,
Vector Laboratories), and detection with the Tyramide Signal Amplification
Direct system (PerkinElmer).
Immunohistological and neuropathological analyses have been described
elsewhere (Valera et al., 2015). To determine a-synuclein accumulation,
neurodegeneration, microgliosis, and astrogliosis, we stained brain sec-
tions with human a-synuclein, NeuN, Iba-1, and GFAP antibodies, res-
pectively. Sections were imaged by Olympus BX41 microscope. The
immunoreactivity levels against human a-synuclein and GFAP were deter-
mined by optical density analysis using the ImageQuant 1.43 program (NIH)
and corrected against background signal levels. The cell numbers of NeuN-
and Iba-1-positive cells were determined per field (230 3 184 mm) of each
animal based on cell body recognition using the ImageQuant 1.43 program
(NIH).
Double Immunofluorescence Labeling Analysis
The procedure for double immunofluorescence labeling analysis has been
described elsewhere (Lee and Lee, 2002). Briefly, blind-coded vibratome sec-
tions were immunolabeled with indicated primary antibodies to determine the
co-localization between Tlr2 and Iba-1, Tlr2 and NeuN, a-synuclein and LC3,
and a-synuclein and TLR2. Immunoreactivities were detected with the Tyra-
mide Signal Amplification Direct system (PerkinElmer) or FITC-tagged second-
ary antibodies. Sections were imaged with a Zeiss 63X (numerical aperture 1.4)
objective on an Axiovert 35 microscope (Zeiss) with an attached MRC 1023
LSCm system (Bio-Rad).
Antibodies and chemicals; cell culture and infection of lentiviral vectors;
qPCR; preparation of cell and tissue extracts; and western blot analysis, elec-
tronmicroscopy analysis, and cytotoxicity analysis are provided in the Supple-
mental Experimental Procedures.
Statistical Analyses
InStat (GraphPad) was used for all statistical analyses. All data were analyzed
for statistical significance by using unpaired t tests or one-way ANOVA. All
data are represented as means ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.09.044.
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